AVCO
Avalon Globocare
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 117.70M; Volume: 3.58M; AvgVol 3m: 873.74K; Beta: 0.55;
Cost estimate:
P/E: –; EPS: -0.20; EPS growth quarter/prev quarter: 33.10%;
EPS growth this year: -122.80%; EPS growth past 5 years: ;
EPS ttm: -0.20;
P/S: 64.02; P/B: 19.17; P/Cashflow: 80.02; P/FCF: ;
Sales: 1.46M; Sales growth quarter/prev quarter: -25.00%; Sales growth past 5 years: ;
Profitability:
Gross Margin: 22.00%; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -148.00%; ROE – return on equity: -309.90%; LT Debt/Equity: 0.70; Total Debt/Equity: 0.00;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 32.40%; Insider Transactions:0.00%;
Institutional Ownership: 3.40%; Institutional Transactions: -3.80%;
Data update: 07/10/2020.